Key result
Pycnogenol increases myocardial catalase ~39% and prevents troponin I elevation in cisplatin-exposed rats.
Why the study?
Does Pycnogenol prevent cisplatin-induced cardiotoxicity in rats?
RCT (n=20)
randomly grouped
Does Pycnogenol prevent cisplatin-induced cardiotoxicity in rats?
Pycnogenol demonstrates a protective effect against cisplatin-induced cardiotoxicity in a rat model by reducing oxidative stress and myocardial injury markers.
Answers are grounded in this paper and cite their sources.
PYC attenuated cisplatin-induced myocardial injury markers in rats; leaves open whether cardioprotection extends to patients.
Öz Amaç: Bu çalışmada sıçan kalbi üzerinde sisplatin (CIS) kardiyotoksisitesi, sıçan miyokardı oksidatif hasarını, troponin I ve serum S100A1 düzeyleri kullanılarak araştırılmıştır.Önceki çalışmalar, Pycnogenol®'un (PYC) hücre koruyucu etkisinin antioksidan ve anti-enflamatuvar özelliklerine bağlı olduğunu bildirmiştir.Bu nedenle, bu çalışmada PYC'nin miyokardiyal koruyucu etkisi araştırılmıştır.Gereç ve Yöntemler: Sıçanlar randomize olarak grup başına 5 olacak şekilde dört gruba ayrıldı.Kontrol grupları, PYC grubu: 10 mg/kg 7 gün boyunca intraperitoneal PYC, 5 gün intraperitoneal olarak sisplatinin 15 mg/kg tek doz enjeksiyonu, sisplatin + PYC grubu: 10 mg/kg PYC intraperitoneal olarak 7 gün boyunca, artı beşinci günde 15 mg/kg tek sisplatin enjeksiyonu.Kalp ve serum örnekleri 8. günde elde edildi.Bulgular: CIS ve PYC eş-tedavi grubunda katalaz seviyesi artmış (43,61±15,16'dan 60,80±21,36'ya, p<0,019) ve troponin I yükselmesi (7,34±6,20'den 3,03±1,36'ya) engellenmiştir.S100A1 seviyesi, CIS ile anlamlı ölçüde azalmıştır.(10,25±8,8'den 3,99±2,87'ye, p<0,035) ve PYC tedavisi (32,07±29,23) ile düzeltilmiştir.Objective: This study investigated the cardiotoxicity of cisplatin (CIS) on rat heart by using the oxidative damage of the rat myocardium, troponin I and serum S100A1 levels.Previous studies have reported that cell-protective effect of Pycnogenol® (PYC) depended on its antioxidant and anti-inflammatory properties.Hence, the myocardial protective effect of PYC was investigated in this study.Materials and Methods: Rats were randomly grouped to four with 5 rats in each group.The groups were consisted of control group, PYC group: 10 mg/kg PYC for 7 days, CIS group: 15 mg/kg single injection of CIS on the 5 th day, CIS + PYC group: 10 mg/kg PYC for 7 days, plus 15 mg/kg single injection of CIS on the 5 th day.Heart and serum samples were acquired subsequently.Results: CIS and PYC co-treatment group had increased catalase level (from 43.61±15.16 to 60.80±21.36,p<0.019) and prevented troponin I elevation (from 7.34±6.20 to 3.03±1.36).The S100A1 level was significantly reduced by CIS (from 10.25±8.8 to 3.99±2.87,p<0.035) and was restored by PYC treatment (32.07±29.23).Conclusion: Injured cardiomyocytes released troponin I after exposure to CIS and PYC, which can protect the cells from CIS cardiotoxicity, increased the tissue catalase level.Additionally, PYC treatment increased serum level of S100A1.
No takes yet. Share an insight, caveat, or question.
Eryılmaz et al. (2017) conducted an RCT in Cisplatin-induced cardiotoxicity (n=20). Pycnogenol vs. Cisplatin alone and control was evaluated on Catalase level (p=<0.019). Pycnogenol co-treatment significantly increased myocardial catalase levels (60.80 vs 43.61, p<0.019) and prevented troponin I elevation in rats exposed to cisplatin.
Synapse has enriched 10 related papers. Consider them for comparative context: